ITRM930301A1 - Procedimento per la preparazione di immunogeni e reagenti diagnostici, e immunogeni e reagenti diagnostici cosi' ottenibili. - Google Patents

Procedimento per la preparazione di immunogeni e reagenti diagnostici, e immunogeni e reagenti diagnostici cosi' ottenibili.

Info

Publication number
ITRM930301A1
ITRM930301A1 IT000301A ITRM930301A ITRM930301A1 IT RM930301 A1 ITRM930301 A1 IT RM930301A1 IT 000301 A IT000301 A IT 000301A IT RM930301 A ITRM930301 A IT RM930301A IT RM930301 A1 ITRM930301 A1 IT RM930301A1
Authority
IT
Italy
Prior art keywords
disease
organism
fragments
derivatives
optional
Prior art date
Application number
IT000301A
Other languages
English (en)
Inventor
Riccardo Cortese
Franco Felici
Alessandra Luzzago
Paolo Monaci
Alfredo Nicosia
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11401749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITRM930301(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Priority to ITRM930301A priority Critical patent/IT1270939B/it
Publication of ITRM930301A0 publication Critical patent/ITRM930301A0/it
Priority to ES94916385T priority patent/ES2120046T3/es
Priority to AU68069/94A priority patent/AU685121B2/en
Priority to DK94916385T priority patent/DK0698091T3/da
Priority to US08/553,257 priority patent/US5994083A/en
Priority to JP6525217A priority patent/JP2813468B2/ja
Priority to CA002160486A priority patent/CA2160486C/en
Priority to AT94916385T priority patent/ATE170558T1/de
Priority to CN94192060A priority patent/CN1093881C/zh
Priority to EP94916385A priority patent/EP0698091B1/en
Priority to BR9406595A priority patent/BR9406595A/pt
Priority to PCT/IT1994/000054 priority patent/WO1994026886A2/en
Priority to RU95122726A priority patent/RU2136697C1/ru
Priority to DE69413024T priority patent/DE69413024T2/de
Publication of ITRM930301A1 publication Critical patent/ITRM930301A1/it
Publication of IT1270939B publication Critical patent/IT1270939B/it
Application granted granted Critical
Priority to HK98112929A priority patent/HK1011710A1/xx
Priority to US09/441,992 priority patent/US6541210B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Rehabilitation Therapy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ITRM930301A 1993-05-11 1993-05-11 Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili. IT1270939B (it)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ITRM930301A IT1270939B (it) 1993-05-11 1993-05-11 Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
DE69413024T DE69413024T2 (de) 1993-05-11 1994-05-05 Verfahren zur herstellung von immunogenen oder diagnostischen reagentien und ebensolche
AT94916385T ATE170558T1 (de) 1993-05-11 1994-05-05 Verfahren zur herstellung von immunogenen oder diagnostischen reagentien und ebensolche
BR9406595A BR9406595A (pt) 1993-05-11 1994-05-05 Processo para a preparação dos imunógenos ou reagentes para diagnóstico que mimetizam um antigeno ou um organismo patogênico especifico para uma doença fagos vacinas contra um agente patogênico especifico e plasmideos pc89 modificados
DK94916385T DK0698091T3 (da) 1993-05-11 1994-05-05 Fremgangsmåde til fremstilling af immunogener eller diagnostiske reagenser samt immunogener eller diagnostiske reagenser op
US08/553,257 US5994083A (en) 1993-05-11 1994-05-05 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
JP6525217A JP2813468B2 (ja) 1993-05-11 1994-05-05 免疫原または診断試薬の製造法、およびその方法によって得られる免疫原または診断試薬
CA002160486A CA2160486C (en) 1993-05-11 1994-05-05 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
ES94916385T ES2120046T3 (es) 1993-05-11 1994-05-05 Procedimiento de preparacion de inmunogenos o reactivos de diagnostico e inmunogenos o reactivos de diagnostico obtenibles por dicho procedimiento.
CN94192060A CN1093881C (zh) 1993-05-11 1994-05-05 免疫原或诊断剂的制备及其获得免疫原或诊断试剂的方法
EP94916385A EP0698091B1 (en) 1993-05-11 1994-05-05 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
AU68069/94A AU685121B2 (en) 1993-05-11 1994-05-05 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
PCT/IT1994/000054 WO1994026886A2 (en) 1993-05-11 1994-05-05 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
RU95122726A RU2136697C1 (ru) 1993-05-11 1994-05-05 Способ получения олигопептидов
HK98112929A HK1011710A1 (en) 1993-05-11 1998-12-08 Process for the preparation of immunogens or diagnostic reagents and immunogens or diagnostic reagents thereby obtainable
US09/441,992 US6541210B1 (en) 1993-05-11 1999-11-18 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM930301A IT1270939B (it) 1993-05-11 1993-05-11 Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.

Publications (3)

Publication Number Publication Date
ITRM930301A0 ITRM930301A0 (it) 1993-05-11
ITRM930301A1 true ITRM930301A1 (it) 1994-11-11
IT1270939B IT1270939B (it) 1997-05-26

Family

ID=11401749

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM930301A IT1270939B (it) 1993-05-11 1993-05-11 Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.

Country Status (15)

Country Link
US (2) US5994083A (it)
EP (1) EP0698091B1 (it)
JP (1) JP2813468B2 (it)
CN (1) CN1093881C (it)
AT (1) ATE170558T1 (it)
AU (1) AU685121B2 (it)
BR (1) BR9406595A (it)
CA (1) CA2160486C (it)
DE (1) DE69413024T2 (it)
DK (1) DK0698091T3 (it)
ES (1) ES2120046T3 (it)
HK (1) HK1011710A1 (it)
IT (1) IT1270939B (it)
RU (1) RU2136697C1 (it)
WO (1) WO1994026886A2 (it)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492807A (en) 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
EP0876615A1 (en) * 1995-11-10 1998-11-11 Elan Corporation Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
FR2762601B3 (fr) * 1997-04-29 1999-06-04 Bio Merieux Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utilisations
IT1291913B1 (it) * 1997-05-22 1999-01-21 Angeletti P Ist Richerche Bio Metodo che prevede l'uso di batteriofagi per la rivelazione della presenza di molecole di interesse in campioni biologici
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO1999033969A1 (en) * 1997-12-31 1999-07-08 Pincus Seth H A method of isolating a peptide which immunologically mimics microbial carbohydrates including group b streptococcal carbohydrates and the use thereof in a vaccine
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
US6413721B1 (en) * 1998-07-24 2002-07-02 Her Majesty the Queen in Right of Canada, as represented by the “Canadian Food Inspection Agency” Methods of isolating common and specific antigens from excretory-secretory products of protostrongylidae
SE9803993D0 (sv) * 1998-11-23 1998-11-23 Bjoern Carlsson New reagent and use thereof
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US9974847B2 (en) * 2000-08-24 2018-05-22 Immunitor USA, Inc. Treatment and prevention of tuberculosis
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7598362B2 (en) 2001-10-11 2009-10-06 Merck & Co., Inc. Hepatitis C virus vaccine
CN1880457B (zh) 2001-10-11 2010-05-26 麦克公司 Ad6重组核酸
US20050019751A1 (en) * 2001-11-09 2005-01-27 Riccardo Cortese Screening for hepatitis c virus entry inhibitors
AU2003213700A1 (en) * 2002-03-01 2003-09-16 Applied Immune Technologies Immunogens for treatment of neoplastic and infectious disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004098529A2 (en) * 2003-04-30 2004-11-18 Emory University Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
JP5475279B2 (ja) 2005-06-17 2014-04-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｃ型肝炎ウイルス核酸ワクチン
WO2007087758A2 (es) * 2006-01-31 2007-08-09 Centro De Ingenieria Genetica Y Biotecnologia Mimotopos de polisacáridos capsulares de neisseria meningitidis y formulaciones farmacéuticas
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
FR2910492B1 (fr) * 2006-12-20 2013-02-15 Bio Modeling Systems Ou Bmsystems Procede de preparation de bacteriophages modifies par insertion de sequences aleatoires dans les proteines de ciblage desdits bacteriophages
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP3241842B1 (en) * 2007-06-26 2024-01-31 F-star Therapeutics Limited Display of binding agents
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN114230632B (zh) * 2021-09-18 2023-01-24 华南农业大学 一种丙烯酰胺衍生物模拟表位肽及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575495A (en) * 1983-05-12 1986-03-11 New York Blood Center, Inc. Synthetic antigenic peptide derived from Hepatitis B surface antigen
WO1986000991A1 (en) * 1984-07-24 1986-02-13 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
WO1986006487A1 (en) * 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
CA2084307A1 (en) * 1990-06-01 1991-12-02 Cetus Oncology Corporation Compositions and methods for identifying biologically active molecules
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
IL99553A0 (en) * 1990-09-28 1992-08-18 Ixsys Inc Compositions containing oligonucleotides linked to expression elements,a kit for the preparation of vectors useful for the expression of a diverse population of random peptides and methods utilizing the same
IL99552A0 (en) * 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
GB9022190D0 (en) * 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5492807A (en) * 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease

Also Published As

Publication number Publication date
EP0698091A1 (en) 1996-02-28
DE69413024T2 (de) 1999-02-04
CA2160486C (en) 2001-02-13
US6541210B1 (en) 2003-04-01
WO1994026886A2 (en) 1994-11-24
US5994083A (en) 1999-11-30
HK1011710A1 (en) 1999-07-16
CN1093881C (zh) 2002-11-06
RU2136697C1 (ru) 1999-09-10
JP2813468B2 (ja) 1998-10-22
CA2160486A1 (en) 1994-11-24
AU685121B2 (en) 1998-01-15
WO1994026886A3 (en) 1995-03-16
DE69413024D1 (de) 1998-10-08
CN1122613A (zh) 1996-05-15
ITRM930301A0 (it) 1993-05-11
ATE170558T1 (de) 1998-09-15
JPH08506493A (ja) 1996-07-16
IT1270939B (it) 1997-05-26
EP0698091B1 (en) 1998-09-02
BR9406595A (pt) 1996-01-02
AU6806994A (en) 1994-12-12
ES2120046T3 (es) 1998-10-16
DK0698091T3 (da) 1999-06-07

Similar Documents

Publication Publication Date Title
ITRM930301A1 (it) Procedimento per la preparazione di immunogeni e reagenti diagnostici, e immunogeni e reagenti diagnostici cosi' ottenibili.
WO1994026886B1 (en) Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
RU95122726A (ru) Способ получения иммуногенов или диагностических реагентов, а также иммуногены и диагностические реагенты, получаемые с его помощью
Burton Phage display
US10323276B2 (en) Adaptive immunity profiling and methods for generation of monoclonal antibodies
Legutki et al. A general method for characterization of humoral immunity induced by a vaccine or infection
EP0138855B1 (en) Method of determining antigenically active amino acid sequences
Karounos et al. Spontaneous expression of antibodies to DNA of various species origin in sera of normal subjects and patients with systemic lupus erythematosus.
JP3135126B2 (ja) 疾患の臨床的発現に基づく、診断用試薬を得る方法、アッセイ、及び治療剤
ES2295292T3 (es) Anticuerpo monoclonal anti-nucleo de vhc.
JP5006923B2 (ja) モノクローナル抗体を産生する方法
AR052377A2 (es) Polipeptidos y polinucleotidos de neisseria meningitidis, un huesped unicelular, un metodo para producir una secuencia de adn, un metodo para producir un polipeptido, un metodo para aislar el antigeno, una composicion farmaceutica, uso de una proteina para producir una vacuna destinada para la preve
NO924780L (no) Ekspresjon av spesifikke immunogener ved bruk av virusantigener
WO2001088162A3 (en) Methods and vectors for generating antibodies in avian species and uses therefor
Jemmerson et al. Mapping antigenic sites on proteins: Implications for the design of synthetic vaccines.
CN115286712B (zh) 新型冠状病毒Delta突变株特异性抗体及其应用
Esterhuysen et al. A liquid-phase blocking ELISA for the detection of antibodies to rabies virus
JPS60155133A (ja) アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン
Zhong et al. Antigenic analysis of the chlamydial 75-kilodalton protein
Tafi et al. Identification of HCV core mimotopes: improved methods for the selection and use of disease-related phage-displayed peptides
CN116284363B (zh) 新型冠状病毒OmicronBA.2/4/5突变株特异性抗体及其应用
Xin et al. A subtractive fluorescence-activated cell-sorting strategy to identify mimotopes of HBV–preS protein from bacterially displayed peptide library
WO2000056144A9 (en) Human sperm surface antigen
CN115819575B (zh) 针对人肿瘤坏死因子-α的单克隆抗体
Oliver et al. Autoantibodies to the cytoskeleton in human sera

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970318